XIBROM Drug Patent Profile
✉ Email this page to a colleague
When do Xibrom patents expire, and what generic alternatives are available?
Xibrom is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in XIBROM is bromfenac sodium. Ten suppliers are listed for this compound. Additional details are available on the bromfenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xibrom
A generic version of XIBROM was approved as bromfenac sodium by SENTISS on January 22nd, 2014.
Summary for XIBROM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Clinical Trials: | 9 |
Patent Applications: | 4,452 |
DailyMed Link: | XIBROM at DailyMed |
Recent Clinical Trials for XIBROM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
InSite Vision | Phase 1/Phase 2 |
Sun Pharma Global FZE | Phase 1/Phase 2 |
Allergan | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for XIBROM
US Patents and Regulatory Information for XIBROM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | XIBROM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-001 | Mar 24, 2005 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XIBROM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | XIBROM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-001 | Mar 24, 2005 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XIBROM
See the table below for patents covering XIBROM around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 162895 | A locally administrable therapeutic composition for inflammatory disease | ⤷ Try a Trial |
Germany | 68902649 | ⤷ Try a Trial | |
Japan | 2683676 | ⤷ Try a Trial | |
Austria | 80043 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XIBROM
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1586316 | 2011C/027 | Belgium | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523 |
1586316 | C300494 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
1586316 | SPC/GB11/054 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 |
1586316 | 122011100019 | Germany | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |